Cancer companies do battle

Article

Zmed, a developer of image-guided radiotherapy equipment, has filed suit against Nomos in Boston federal court, alleging patent infringement by Nomos in its recently released ImageSync software on the company's tumor localization system. Zmed's SonArray,

Zmed, a developer of image-guided radiotherapy equipment, has filed suit against Nomos in Boston federal court, alleging patent infringement by Nomos in its recently released ImageSync software on the company's tumor localization system. Zmed's SonArray, an ultrasound-guided adaptive positioning system, uses stereotactic optical guidance and 3D matching software to align the tumor target to the isocenter of the radiotherapy beam. Nomos contends that its new BAT SXi device, which also uses ultrasound to align the radiation beam, does not infringe the Zmed patent, and Nomos has promised to vigorously defend itself against the litigation. Both companies claim victory in a similar court case involving the two last year.

Recent Videos
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
Related Content
© 2025 MJH Life Sciences

All rights reserved.